Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CORT Corcept Therapeutics

Market Closed 02-27 16:00:00 EST

35.70

-0.08

-0.22%

盘后35.74

+0.04+0.11%

19:52 EST

High35.74	Low34.57	Vol1.41M
Open35.21	D1 Closing35.78	Amplitude3.27%
Mkt Cap3.80B	Tradable Cap3.10B	Total Shares106.37M
T/O49.73M	T/O Rate1.62%	Tradable Shares86.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CORT","market":"US","secType":"STK","nameCN":"Corcept Therapeutics","latestPrice":35.7,"timestamp":1772226000000,"preClose":35.78,"halted":0,"volume":1408954,"hourTrading":{"tag":"盘后","latestPrice":35.74,"preClose":35.7,"latestTime":"19:52 EST","volume":85439,"amount":3050108.1516,"timestamp":1772239921175,"change":0.04,"changeRate":0.00112,"amplitude":0.00112},"delay":0,"changeRate":-0.0022358859698154918,"floatShares":86875270,"shares":106374020,"eps":0.82,"marketStatus":"Market Closed","change":-0.08,"latestTime":"02-27 16:00:00 EST","open":35.21,"high":35.74,"low":34.57,"amount":49732958.184798,"amplitude":0.0327,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.82,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1081915200000,"exchange":"NASDAQ","adjPreClose":35.78,"preHourTrading":{"tag":"盘前","latestPrice":35,"preClose":35.78,"latestTime":"08:57 EST","volume":343,"amount":12027.58998,"timestamp":1772200677789,"change":-0.78,"changeRate":-0.0218,"amplitude":0.027557},"postHourTrading":{"tag":"盘后","latestPrice":35.74,"preClose":35.7,"latestTime":"19:52 EST","volume":85439,"amount":3050108.1516,"timestamp":1772239921175,"change":0.04,"changeRate":0.00112,"amplitude":0.00112},"volumeRatio":0.6542067877638855,"impliedVol":0.564,"impliedVolPercentile":0.2988},"requestUrl":"/m/hq/s/CORT/tweets","defaultTab":"tweets","newsList":[{"id":"2614898508","title":"Rosen Law Firm Urges Corcept Investors to Seek Counsel Before April 21 Lead Plaintiff Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2614898508","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614898508?lang=en_us&edition=fundamental","pubTime":"2026-02-28 06:30","pubTimestamp":1772231423,"startTime":"0","endTime":"0","summary":"A securities class action lawsuit has been filed on behalf of investors who bought Corcept Therapeutics common stock between Oct. 31, 2024 and Dec. 30, 2025. The complaint alleges the company misled investors about the strength of clinical evidence and regulatory prospects for its relacorilant new drug application, and says investors were harmed when concerns about FDA approval risk emerged. Investors seeking to be appointed lead plaintiff must file a motion by April 21, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL3yGSQr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4532","NDAQ","BK4007","SG9999014013.SGD","CORT","IE00B64PRP62.GBP","LU2210149790.SGD","LU1559883803.SGD","SG9999014005.SGD","BK4585","IE00B3QW5Z07.USD","BK4588","LU2210150020.SGD","SG9999014021.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","LU0566484027.USD","BK4112"],"gpt_icon":0},{"id":"2614928007","title":"Portnoy Law Firm Files Class Action Against Corcept Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2614928007","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614928007?lang=en_us&edition=fundamental","pubTime":"2026-02-27 11:40","pubTimestamp":1772163623,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed on behalf of investors in Corcept Therapeutics Incorporated who purchased securities between Oct. 31, 2024 and Dec. 31, 2025. The complaint alleges the company misled investors about the strength of clinical evidence and the likelihood of FDA approval for its relacorilant new drug application, before disclosing it had received an FDA Complete Response Letter seeking additional evidence of effectiveness, after which Corcept shares fell more than 50%. Investors have until April 21, 2026 to seek appointment as lead plaintiff.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL2XtvFD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LU1559883803.SGD","BK4112","BK4007","LU0314104364.USD","SG9999014005.SGD","SG9999014039.USD","NDAQ","IE00BKPKM429.USD","CORT","IE00B64PRP62.GBP","LU2095319765.USD","LU2210149790.SGD","LU0566484027.USD","BK4532","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","SG9999014021.USD","BK4588"],"gpt_icon":0},{"id":"2614047011","title":"Robbins LLP Alerts Corcept Investors to Lead Plaintiff Deadline in Class Action Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2614047011","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614047011?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:00","pubTimestamp":1772114443,"startTime":"0","endTime":"0","summary":"A securities class action lawsuit has been filed against Corcept Therapeutics Incorporated on behalf of investors who bought the company’s common stock between October 31, 2024 and December 30, 2025. The suit alleges the company misled investors about the strength of clinical evidence and the likelihood of FDA approval for its drug candidate relacorilant for hypercortisolism, before the FDA issued a Complete Response Letter on December 31, 2025 seeking additional evidence of effectiveness, triggering a sharp stock decline.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL5Gj3S5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","LU0566484027.USD","LU2210149790.SGD","LU2210150020.SGD","BK4007","LU0314104364.USD","BK4588","BK4532","IE00BGHQF748.EUR","CORT","LU2095319765.USD","BK4112","BK4585","IE00BKPKM429.USD","SG9999014005.SGD","NDAQ","SG9999014039.USD"],"gpt_icon":0},{"id":"2614067882","title":"Lead Plaintiff Deadline Set in Corcept Therapeutics Securities Class Action","url":"https://stock-news.laohu8.com/highlight/detail?id=2614067882","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614067882?lang=en_us&edition=fundamental","pubTime":"2026-02-26 11:14","pubTimestamp":1772075681,"startTime":"0","endTime":"0","summary":"A securities class action lawsuit has been filed against Corcept Therapeutics Incorporated in the U.S. District Court for the Northern District of California. The case covers investors who bought or acquired Corcept shares between Oct. 31, 2024 and Dec. 30, 2025, and investors seeking to serve as lead plaintiff must file an application by April 21, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL2QmN44:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD","CORT","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4532","BK4112","LU0566484027.USD","SG9999014013.SGD","BK4007","LU2095319765.USD","BK4588","SG9999014021.USD","LU2210150020.SGD","SG9999014039.USD","LU2210149790.SGD","LU1559883803.SGD","BK4585","SG9999014005.SGD","LU0314104364.USD"],"gpt_icon":0},{"id":"1156227825","title":"Stock Track | Corcept Therapeutics Plummets 5.15% Intraday Following Analyst Price Target Cuts","url":"https://stock-news.laohu8.com/highlight/detail?id=1156227825","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156227825?lang=en_us&edition=fundamental","pubTime":"2026-02-26 01:22","pubTimestamp":1772040142,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (CORT) stock plummeted 5.15% during intraday trading on Wednesday, as the market reacted to negative analyst sentiment.The decline follows reports that at least two major...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CORT"],"gpt_icon":0},{"id":"2614084562","title":"Corcept Therapeutics Inc : Piper Sandler Cuts Target Price to $73 From $121","url":"https://stock-news.laohu8.com/highlight/detail?id=2614084562","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614084562?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:31","pubTimestamp":1772022714,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL1H8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LU1559883803.SGD","BK4532","LU0566484027.USD","CORT"],"gpt_icon":0},{"id":"2614308900","title":"Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2614308900","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614308900?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:03","pubTimestamp":1772020980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CORT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2026 07:03 ET (12:03 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"gpt_icon":0},{"id":"2614085482","title":"Corcept Therapeutics price target lowered to $60 from $67 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2614085482","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614085482?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:13","pubTimestamp":1772018005,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Corcept Therapeutics (CORT) to $60 from $67 and keeps a Buy ratin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-price-target-lowered-to-60-from-67-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-price-target-lowered-to-60-from-67-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT"],"gpt_icon":0},{"id":"2614858000","title":"Corcept Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $60 From $67","url":"https://stock-news.laohu8.com/highlight/detail?id=2614858000","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614858000?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:06","pubTimestamp":1772017577,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nAZN4SI9HA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CORT","BK4532","LU1559883803.SGD","BK4007","LU0566484027.USD"],"gpt_icon":0},{"id":"2614213703","title":"U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP","url":"https://stock-news.laohu8.com/highlight/detail?id=2614213703","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614213703?lang=en_us&edition=fundamental","pubTime":"2026-02-25 15:20","pubTimestamp":1772004027,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HPFeb 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Chevron, GoDaddy and HP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL4N3ZL0IC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDNA","BBIO","BMRN","CAT","BMY","GLW","AMDU","BEAM","CSGP","ADUS","BIOA","AMDL","BAM","AU","CORT","CRL","IPSC","AMT","BURL","CEG","ICRC","CZR","AMDY","CRCL","CECO","ABBV","AMUU","AMDD","ATRO","CCUP","CEGX","CRBG","CRCD","CVX","AFL","AMD","BOW","AMDG","CAVA","AVB","AUGO","AXON","ALMS","CRCG","CYTK","SAM","BWIN","ANGX","BCC","AMYY"],"gpt_icon":0},{"id":"2614775517","title":"Investors File Securities Fraud Class Action Against Corcept Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2614775517","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614775517?lang=en_us&edition=fundamental","pubTime":"2026-02-25 10:49","pubTimestamp":1771987744,"startTime":"0","endTime":"0","summary":"A securities fraud class action lawsuit has been filed against Corcept Therapeutics Incorporated in the U.S. District Court for the Northern District of California on behalf of investors who acquired shares between Oct. 31, 2024 and Dec. 30, 2025. The suit alleges the company and certain executives failed to disclose material information about the likelihood of FDA approval for relacorilant, after the FDA issued a Complete Response Letter seeking additional evidence of effectiveness. Corcept shares fell 50.4% on Dec. 31, 2025 following the disclosure, and investors have until April 21, 2026 to seek appointment as lead plaintiff.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL7MYPr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","CORT","BK4007","NDAQ","SG9999014039.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4588","LU0566484027.USD","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","LU1559883803.SGD","BK4532","BK4585","IE00BKPKM429.USD","SG9999014021.USD","SG9999014013.SGD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2614748725","title":"Corcept Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2614748725","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614748725?lang=en_us&edition=fundamental","pubTime":"2026-02-25 06:01","pubTimestamp":1771970469,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics Inc reports results for the quarter ended September 30 - Earnings SummaryCorcept Therapeutics Inc CORT.OQ reported quarterly adjusted earnings of 20 cents per share for the quarte","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL8N3ZK2WO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT","BK4007","LU0566484027.USD","LU1559883803.SGD","BK4532"],"gpt_icon":0},{"id":"1100546116","title":"Stock Track | Corcept Therapeutics Plunges 5.43% After-Hours on Q4 Earnings and Revenue Misses","url":"https://stock-news.laohu8.com/highlight/detail?id=1100546116","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100546116?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:58","pubTimestamp":1771970326,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics' stock experienced a significant after-hours plunge of 5.43% on Tuesday, following the release of its fourth-quarter financial results.The company reported Q4 earnings per share...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CORT"],"gpt_icon":0},{"id":"2614887725","title":"Corcept Therapeutics Posts Strong 2025 Results, Issues Optimistic Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2614887725","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614887725?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:36","pubTimestamp":1771968960,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics ( ($CORT) ) has provided an update. On February 24, 2026, Corcept Therapeutics reported audited fourth-quarter and full-year 2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/corcept-therapeutics-posts-strong-2025-results-issues-optimistic-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/corcept-therapeutics-posts-strong-2025-results-issues-optimistic-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LU1559883803.SGD","LU0566484027.USD","BK4532","CORT"],"gpt_icon":0},{"id":"2614723381","title":"Corcept Therapeutics misses Q4 revenue expectations, net income drops 21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614723381","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614723381?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:20","pubTimestamp":1771968048,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics missesQ4 revenue expectations, net income drops 21%OverviewEndocrinologic medication developer's Q4 revenue missed analysts' expectationsCompany's Q4 net income declined 21% from ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL1N3ZK1B6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1559883803.SGD","CORT","LU0566484027.USD","BK4007"],"gpt_icon":0},{"id":"2614740705","title":"Corcept Q4 product revenue hits USD 202.1 million +37% tablets sold","url":"https://stock-news.laohu8.com/highlight/detail?id=2614740705","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614740705?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:08","pubTimestamp":1771967305,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire  on February 24, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL9nvbpw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1559883803.SGD","CORT","LU0566484027.USD","BK4007"],"gpt_icon":0},{"id":"2614740272","title":"Corcept Therapeutics Q4 EPS $0.20 Misses $0.27 Estimate, Sales $202.125M Miss $254.936M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2614740272","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614740272?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:06","pubTimestamp":1771967213,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics Q4 EPS $0.20 Misses $0.27 Estimate, Sales $202.125M Miss $254.936M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50832667/corcept-therapeutics-q4-eps-0-20-misses-0-27-estimate-sales-202-125m-miss-254-936m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Therapeutics Q4 EPS $0.20 Misses $0.27 Estimate, Sales $202.125M Miss $254.936M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"gpt_icon":0},{"id":"2614874025","title":"BRIEF-Corcept Therapeutics Q4 EPS USD 0.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2614874025","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614874025?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:05","pubTimestamp":1771967148,"startTime":"0","endTime":"0","summary":"BRIEF-Corcept Therapeutics Q4 EPS USD 0.2\n\n\nFeb 24 (Reuters) - Corcept Therapeutics Q4 net income USD 24.288 million.\n\nQ4 revenue USD 202.125 million vs. IBES estimate USD 254.9 million\noutlook FY revenue USD 900-1,000 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nPLX8081A2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","CORT","BK4007","LU1559883803.SGD","LU0566484027.USD"],"gpt_icon":0},{"id":"2614740919","title":"Corcept Therapeutics Outlook FY Revenue USD 900-1,000 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614740919","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614740919?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:05","pubTimestamp":1771967104,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nPLX8081A2:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0566484027.USD","LU1559883803.SGD","BK4007","CORT","BK4532"],"gpt_icon":0},{"id":"2614740418","title":"Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2614740418","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614740418?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:05","pubTimestamp":1771967104,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA9FP5QZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4532","CORT","LU1559883803.SGD","LU0566484027.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corcept.com","stockEarnings":[{"period":"1week","weight":0.0253},{"period":"1month","weight":-0.2214},{"period":"3month","weight":-0.5504},{"period":"6month","weight":-0.488},{"period":"1year","weight":-0.4035},{"period":"ytd","weight":0.0259}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.022337},{"month":2,"riseRate":0.409091,"avgChangeRate":0.008661},{"month":3,"riseRate":0.761905,"avgChangeRate":0.141286},{"month":4,"riseRate":0.52381,"avgChangeRate":-0.001402},{"month":5,"riseRate":0.5,"avgChangeRate":0.00703},{"month":6,"riseRate":0.454545,"avgChangeRate":0.039099},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.006529},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.006283},{"month":9,"riseRate":0.454545,"avgChangeRate":0.062175},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005789},{"month":11,"riseRate":0.5,"avgChangeRate":0.018834},{"month":12,"riseRate":0.409091,"avgChangeRate":0.027449}],"exchange":"NASDAQ","name":"Corcept Therapeutics","nameEN":"Corcept Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corcept Therapeutics,CORT,Corcept Therapeutics股票,Corcept Therapeutics股票老虎,Corcept Therapeutics股票老虎国际,Corcept Therapeutics行情,Corcept Therapeutics股票行情,Corcept Therapeutics股价,Corcept Therapeutics股市,Corcept Therapeutics股票价格,Corcept Therapeutics股票交易,Corcept Therapeutics股票购买,Corcept Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}